Nachrichten zur Cytokinetics Aktie

Cytokinetics CEO on shares soaring, heart drug Aficamten and American heart health

Robert Blum, Cytokinetics CEO, joins The Exchange to discuss the biotech sector, the companys shares soaring on the latest trial…

Needham says Cytokinetics appeal as M&A target enhanced by HCM data

…

Wall Street bullish on Cytokinetics following positive trial results By Investing.com

Wall Street bullish on Cytokinetics following positive trial results…

Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals

Cytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock…

Biotech Stock Roundup: BMYs KRTX and RYZB Acquisition, CYTK Surges on Study Data

Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.…

Cytokinetics gains on positive Phase 3 data for heart disease therapy (update)

…

Cytokinetics may be worth $90+ a share in potential deal amid Phase 3 data - UFP

…

Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade)

…

Cytokinetics stock rockets toward a 19-year high after positive trial data on heart disease treatment

…

Cytokinetics Stock Jumps on Heart Drug Trials Results

The biotech sectors heady end-of-year continued Wednesday, with shares of Cytokinetics surging after the company said its experimental heart drug…

Cytokinetics: Buyout Rumors Ahead Of The Key Phase 3 Readout Of Aficamten

…

Cytokinetics gains amid report of Novartis, AstaZeneca takeover interest

…

Cytokinetics Announces Five Presentations at the 34th International Symposium on ALS/MND

Results from COURAGE-ALS to Be Presented on December 7, 2023 Results from COURAGE-ALS to Be Presented on December 7, 2023…

Investing in Cytokinetics (NASDAQ:CYTK) five years ago would have delivered you a 313% gain

It hasnt been the best quarter for Cytokinetics, Incorporated ( NASDAQ:CYTK ) shareholders, since the share price has...…

Cytokinetics, Incorporated (CYTK) Q3 2023 Earnings Call Transcript

…

Potential Cytokinetics acquirer might wait until pivotal data

Potential Cytokinetics acquirer might wait until pivotal data - Truist…

Insiderhandel: President & CEO verkauft Aktien von Cytokinetics im Wert von 404.589$

Blum, Robert I. - Vorstand - Tag der Transaktion: 2023-08-11...…

Form 8-K CYTOKINETICS INC For: Aug 03

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on…

Cytokinetics to Announce Second Quarter Results on August 3, 2023

SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it…

Insiderhandel: President & CEO verkauft Aktien von Cytokinetics im Wert von 407.500$

Blum, Robert I. - Vorstand - Tag der Transaktion: 2023-07-03...…

Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

First Phase 3 Trial Evaluating Monotherapy with a Cardiac Myosin Inhibitor Compared to Monotherapy with a Beta Blocker in Adults…

Insiderhandel: President & CEO verkauft Aktien von Cytokinetics im Wert von 463.250$

Blum, Robert I. - Vorstand - Tag der Transaktion: 2023-06-12...…

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on…

Insiderhandel: President & CEO verkauft Aktien von Cytokinetics im Wert von 470.875$

Blum, Robert I. - Vorstand - Tag der Transaktion: 2023-05-31...…

Cytokinetics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the…

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586

Advancement of Additional Cardiac Myosin Inhibitor Expands Specialty Cardiovascular Portfolio Advancement of Additional Cardiac Myosin Inhibitor Expands Specialty Cardiovascular Portfolio...…

Form 8-K CYTOKINETICS INC For: May 11

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K CYTOKINETICS INC For: May 10

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 10-Q CYTOKINETICS INC For: Mar 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: EVP Research & Development verkauft Aktien von Cytokinetics im Wert von 280.000$

Malik, Fady Ibraham - Vorstand - Tag der Transaktion: 2023-05-03...…

Insiderhandel: President & CEO verkauft Aktien von Cytokinetics im Wert von 471.000$

Blum, Robert I. - Vorstand - Tag der Transaktion: 2023-04-28...…

Cytokinetics to Announce First Quarter Results on May 4, 2023

SOUTH SAN FRANCISCO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it…

Analyst Ratings for Cytokinetics

Latest Ratings for CYTK DateFirmActionFromTo Dec 2021OppenheimerInitiates Coverage OnOutperform Dec 2021HC Wainwright & Co.MaintainsBuy Dec 2021JP MorganInitiates Coverage OnOverweight…

Insiderhandel: President & CEO verkauft Aktien von Cytokinetics im Wert von 445.125$

Blum, Robert I. - Vorstand - Tag der Transaktion: 2023-04-14...…

Insiderhandel: EVP Research & Development verkauft Aktien von Cytokinetics im Wert von 136.840$

Malik, Fady Ibraham - Vorstand - Tag der Transaktion: 2023-04-13...…

Cytokinetics (CYTK) Dips 20% so Far in 2023 on Setbacks

Cytokinetics (CYTK) declines 20% in the year so far as it suffers a regulatory setback for its NDA for omecamtiv…

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on…

Cytokinetics to focus on heart disease drug after ALS trial failure

...By Khushi Mandowara (Reuters) -Cytokinetics Inc said on Friday......…

Cytokinetics stops development of ALS drug

...March 31 (Reuters) - Cytokinetics Inc said on Friday it had stopped......…

Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis

Company Plans to Discontinue the Phase 3 Clinical Trial of Reldesemtiv After Data Monitoring Committee Found No Effect on Primary…

Form 8-K CYTOKINETICS INC For: Mar 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: President & CEO verkauft Aktien von Cytokinetics im Wert von 438.125$

Blum, Robert I. - Vorstand - Tag der Transaktion: 2023-03-28...…

Cytokinetics Releases Inaugural Corporate Responsibility Report

Report Highlights Company Commitment to Patient Centricity, Sustainability, Ethics, Diversity, Equity and Inclusion Report Highlights Company Commitment to Patient Centricity,…

Insiderhandel: EVP Research & Development verkauft Aktien von Cytokinetics im Wert von 156.400$

Malik, Fady Ibraham - Vorstand - Tag der Transaktion: 2023-03-09...…

Cytokinetics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the…

Form 8-K CYTOKINETICS INC For: Mar 04

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session

Treatment with Aficamten Resulted in Significant Improvements in Heart Failure Symptoms and Cardiac Biomarkers in Patients with Non-Obstructive HCM, Supporting Advancement…

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on…

Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of -18.85% and 73.77%, respectively, for the quarter ended December 2022. Do the…